The genesis of colorectal and pancreatic cancer involves the interaction of environmental and heritable causes. Key to discoveries in diagnosis and treatment of these malignancies is the understanding of these factors by investigation of well-characterized and available patient data and specimens. The goal of CORE 3 is to provided SPORE and other investigators with these materials to support the research of familial, environmental and molecular genetic factors in both colorectal and pancreatic cancer. With this regard, a registry and clinical study of patients with hereditary colorectal cancer and polyposis syndromes were founded at the Johns Hopkins Hospital in 1973. In 1982, the Bowel Tumor Working Group was formed to study the pathobiology and molecular genetics of colorectal tumors. In 1991 the CORE 3 was formed. The CORE is maintained in computerized Access and Progeny data bases and includes: 1) families with a history of familial aggregation of colorectal cancer, early onset colorectal cancer and polyposis syndromes and 2) family histories and food frequency questionnaires on patients evaluated for colorectal neoplasm. The CORE was expanded in 1996 to include similar data on pancreatic cancer patients.
The specific aims of CORE 3 are: 1. To collect family history, medical history, pathological records, environmental/exposure data and dietary date from at risk and affected individuals with colorectal and pancreatic neoplasm and associated syndromes. 2. To procure specimens including blood and stool in at risk and affected individuals with colorectal and pancreatic neoplasm and associated syndromes.
The importance of the knowledge gained by the data accumulated by this CORE is significant and multifactorial. Benefits from this knowledge might include risk markers necessary for the initiation of preventive surveillance strategies, diagnostic markers essential to the appropriate medical and surgical treatment of these tumors, and therapeutic targets needed for the development of medical therapies.
|Llosa, Nicolas J; Cruise, Michael; Tam, Ada et al. (2015) The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints. Cancer Discov 5:43-51|
|Eshleman, James R; Norris, Alexis L; Sadakari, Yoshihiko et al. (2015) KRAS and guanine nucleotide-binding protein mutations in pancreatic juice collected from the duodenum of patients at high risk for neoplasia undergoing endoscopic ultrasound. Clin Gastroenterol Hepatol 13:963-9.e4|
|Zhen, David B; Rabe, Kari G; Gallinger, Steven et al. (2015) BRCA1, BRCA2, PALB2, and CDKN2A mutations in familial pancreatic cancer: a PACGENE study. Genet Med 17:569-77|
|Patel, Kalpesh; Iacobuzio-Donahue, Christine A; Gormley, Paul E et al. (2015) Are we systematically under-dosing patients with fluorouracil? J Clin Oncol 33:e36-7|
|De Remigis, Alessandra; de Gruijl, Tanja D; Uram, Jennifer N et al. (2015) Development of thyroglobulin antibodies after GVAX immunotherapy is associated with prolonged survival. Int J Cancer 136:127-37|
|Sutcliffe, Catherine G; Schultz, Kathleen; Brannock, Julitta M et al. (2015) Do people know whether they are overweight? Concordance of self-reported, interviewer-observed, and measured body size. Cancer Causes Control 26:91-8|
|Black, Chelsea M; Armstrong, Todd D; Jaffee, Elizabeth M (2014) Apoptosis-regulated low-avidity cancer-specific CD8(+) T cells can be rescued to eliminate HER2/neu-expressing tumors by costimulatory agonists in tolerized mice. Cancer Immunol Res 2:307-19|
|Kojima, Masatsugu; Murata, Satoshi; Mekata, Eiji et al. (2014) Fusion protein of mutant B7-DC and Fc enhances the antitumor immune effect of GM-CSF-secreting whole-cell vaccine. J Immunother 37:147-54|
|Wu, Xinyan; Renuse, Santosh; Sahasrabuddhe, Nandini A et al. (2014) Activation of diverse signalling pathways by oncogenic PIK3CA mutations. Nat Commun 5:4961|
|Amato, Eliana; Molin, Marco Dal; Mafficini, Andrea et al. (2014) Targeted next-generation sequencing of cancer genes dissects the molecular profiles of intraductal papillary neoplasms of the pancreas. J Pathol 233:217-27|
Showing the most recent 10 out of 633 publications